BioventusBVS
About: Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. Geographical presence is in the United States which derives key revenue, and International markets.
Employees: 930
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
126% more call options, than puts
Call options by funds: $823K | Put options by funds: $364K
17% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 47
1.68% more ownership
Funds ownership: 69.62% [Q4 2024] → 71.31% (+1.68%) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q4 2024] → 3 (+0) [Q1 2025]
4% less funds holding
Funds holding: 151 [Q4 2024] → 145 (-6) [Q1 2025]
6% less capital invested
Capital invested by funds: $478M [Q4 2024] → $448M (-$29.6M) [Q1 2025]
18% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 22
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Cantor Fitzgerald Ross Osborn | 83%upside $12 | Overweight Initiated | 7 Jul 2025 |
Financial journalist opinion
